![Page 1: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/1.jpg)
2006 : TERAPIA ORMONALE SOSTITUTIVA
DELLA MENOPAUSA
CURRENT CONSENSUS GUIDELINES AND
PRACTICE RECOMMENDATIONS
Andrea R. Genazzani, MD, PhD, FRCOG
President of the International Society of Gynecological EndocrinologyDirector of the Department of Obstetrics and Gynecology
University of Pisa
Research Support, Grants and Occasional Honoraria: Bracco, Eli Lilly&Company, Igea, Lunar Corporation, MS&D, Novartis, Novo Nordisk, Organon, Pfizer, P&G, Schering, Solvay, Wyeth.
![Page 2: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/2.jpg)
![Page 3: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/3.jpg)
An About-Face On Hormone Therapy
New Study Shows HRT May Actually
Improve Heart Health in Some Women:
Timing Is Key
By Tara Parker-Pope, The Wall Street Journal Jan 24, 2006
![Page 4: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/4.jpg)
Guideline and Consensus Recommendations Practice in areas of controversy can be difficult
HRT has been controversial since 1998
HRT Evidence Base is progressively evolving
Authoritative recommendations provide guidance and a degree of security for practice in these circumstances
Recommendations
Government bodies
International organisations
Consensus Groups
![Page 5: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/5.jpg)
Guideline and Consensus Recommendations Practice in areas of controversy can be difficult
HRT has been controversial since 1998
HRT Evidence Base is progressively evolving
Authoritative recommendations provide guidance and a degree of security for practice in these circumstances
Recommendations
Government bodies
International organisations
Consensus Groups
![Page 6: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/6.jpg)
Guideline and Consensus Recommendations Practice in areas of controversy can be difficult
HRT has been controversial since 1998
HRT Evidence Base is progressively evolving
Authoritative recommendations provide guidance and a degree of security for practice in these circumstances
Recommendations
Government bodies
International organisations
Consensus Groups
![Page 7: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/7.jpg)
Guideline and Consensus Recommendations
Government Guidance is minimal EMEA statement
International Societies
International Menopause Society (IMS)
European Menopause and Andropause Society (EMAS)
North American Menopause Society (NAMS)
Consensus Group Recommendations
International Consensus Group
Rome 2003
Lucerne 2004
![Page 8: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/8.jpg)
Guideline and Consensus Recommendations
Government Guidance is minimal EMEA statement
International Societies
International Menopause Society (IMS)
European Menopause and Andropause Society (EMAS)
North American Menopause Society (NAMS)
Consensus Group Recommendations
International Consensus Group
Rome 2003
Lucerne 2004
![Page 9: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/9.jpg)
Guideline and Consensus Recommendations
Government Guidance is minimal EMEA statement
International Societies
International Menopause Society (IMS)
European Menopause and Andropause Society (EMAS)
North American Menopause Society (NAMS)
Consensus Group Recommendations
International Consensus Group
Rome 2003
Lucerne 2004
![Page 10: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/10.jpg)
EMEA Guidance - Dec 2003
![Page 11: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/11.jpg)
HRT no longer first choice for preventing osteoporosis
![Page 12: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/12.jpg)
these EMEA recommendations are unjustified by: Physiology Epidemiology Pharmachology Evidence Based Medicine
![Page 13: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/13.jpg)
Statement from The International Menopause Society
The International Menopause Society (IMS) is profoundly concerned that the European Medicines Evaluation Agency (EMEA) has ignored important information in its decision to recommend that the risk/benefit balance of hormone replacement therapy (HRT) does not justify its use as first-line therapy for the indication for prevention of osteoporosis in women.In early postmenopausal women, there is no evidence that alternative treatments are as beneficial……Because of the age of the population studied in the WHI, safety concerns cannot be extrapolated to early postmenopausal women…………...Therefore, the IMS considers that the EMEA recommendations are unjustified and potentially harmful for the health of postmenopausal women.
http://www.imsociety.org/pages/news.html
![Page 14: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/14.jpg)
EMEA – MHRA Guidance - Dec 2003
HRT provides effective relief of climacteric (vasomotor) symptoms typically occurring around the menopause
The risk:benefit of HRT is favourable for treatment of vasomotor symptoms
The risk:benefit balance of HRT is not favourable as first-line treatment for the prevention of osteoporosis or osteoporotic fractures in women…
- with risk factors
or
- established osteoporosis
![Page 15: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/15.jpg)
EMEA – MHRA Guidance - Dec 2003
HRT provides effective relief of climacteric (vasomotor) symptoms typically occurring around the menopause
The risk:benefit of HRT is favourable for treatment of vasomotor symptoms
The risk:benefit balance of HRT is not favourable as first-line treatment for the prevention of osteoporosis or osteoporotic fractures in women…
- with risk factors
or
- established osteoporosis
![Page 16: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/16.jpg)
Climacteric 2004; 7: 333-7
![Page 17: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/17.jpg)
IMS Position Statement
Section 1
Critique of WHI and other recent studies
Section 2
Summary recommendations for practice
Climacteric 2004; 7: 333-7
![Page 18: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/18.jpg)
![Page 19: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/19.jpg)
EMAS Position Statement
Section 1
Critique of WHI and other recent studies
Section 2
Recommendations for practice with evidence gradings
Maturitas 2005; 51: 8-14
![Page 20: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/20.jpg)
North American Menopause Society Position Statement
Menopause 2004. 11; 589-600
![Page 21: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/21.jpg)
NAMS Position Statement
Recommendations from Expert Panel Consensus Group – telephone & electronic communication
Discussion of measures of risk and the nature of different types of study
Recommendations for practice
areas of consensus
areas where insufficient or conflicting evidence precludes consensus
the need for future research
Menopause 2004. 11; 589-600
![Page 22: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/22.jpg)
International Consensus Group Rome 2003, Lucerne 2004
Climacteric 2004 7: 210-216
![Page 23: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/23.jpg)
International Consensus Group Rome 2003, Lucerne 2004
International Expert Group
Extended Consensus Meetings
Burger H (AUS)
Archer DF (USA) Barlow D (UK) Birkhäuser M (CH)Calaf-Alsina J (E) Gambacciani M (I) Genazzani A (I)Hadji P (GER) Iversen OE (N) Kuhl H (GER)Lobo RA (USA) Maudelonde T (F) Neves e Castro M (P)Notelovitz M (USA) Palacios S (E) Paszkowski T (PL)Peer E (IL) Pines A (IL) Samsioe G (SWE)Stevenson J (UK) Skouby S (DK) Sturdee D (UK)de Villiers T (RSA) Whitehead M (UK) Ylikorkala O (FIN)
Climacteric 2004 7: 210-216
![Page 24: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/24.jpg)
International Consensus Group Rome 2003, Lucerne 2004
International Expert Group
Extended Consensus Meetings
Draft Practical Recommendations drafted at meeting by group leaders
Henry Burger & David Archer
Comments received from Group in discussion at meeting and by subsequent electronic communication
Final Recommendations published
Climacteric 2004 7: 210-216
![Page 25: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/25.jpg)
Indications
HRT should only be prescribed when it is clearly indicated
Vasomotor symptoms (there is no effective alternative)
Urogenital atrophy (Topical low-dose products are the treatment choice if only local symptoms present
Fracture risk reduction (HRT may be an initial option in woman at significantly increased fracture risk)
![Page 26: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/26.jpg)
Indications
HRT should only be prescribed when it is clearly indicated
Vasomotor symptoms (there is no effective alternative)
Urogenital atrophy (Topical low-dose products are the treatment choice if only local symptoms present
Fracture risk reduction (HRT may be an initial option in woman at significantly increased fracture risk)
![Page 27: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/27.jpg)
Indications
HRT should only be prescribed when it is clearly indicated
Vasomotor symptoms (there is no effective alternative)
Central reason for use of HRT
All guidelines endorse this use (including EMEA advice)
Evidence base secure
No equivalently effective alternative
![Page 28: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/28.jpg)
Indications
HRT should only be prescribed when it is clearly indicated
Vasomotor symptoms (there is no effective alternative)
Urogenital atrophy (Topical low-dose products are the treatment choice if only local symptoms present
Fracture risk reduction (HRT may be an initial option in woman at significantly increased fracture risk)
![Page 29: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/29.jpg)
Indications
HRT should only be prescribed when it is clearly indicated
Vasomotor symptoms (there is no effective alternative)
Urogenital atrophy (Topical low-dose products are the treatment choice if only local symptoms present
Important indication for estrogen use
All guidelines endorse this
Local E-only suggested by NAMS & EMAS
Likely to be long term indication (EMAS)
![Page 30: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/30.jpg)
Indications
HRT should only be prescribed when it is clearly indicated
Vasomotor symptoms (there is no effective alternative)
Urogenital atrophy (Topical low-dose products are the treatment choice if only local symptoms present
Fracture risk reduction (HRT may be an initial option in woman at significantly increased fracture risk)
Evidence agreed by all guidelines
Duration of use needs to be long-term for effective action
no complete consensus from guidelines
![Page 31: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/31.jpg)
IndicationsHRT should only be prescribed when it is clearly indicated
Fracture risk reduction (HRT may be an initial option in woman at significantly increased fracture risk)
Evidence agreed by all guidelines
Duration of use needs to be long-term for effective action
no complete consensus from guidelines
EMEA – not first-line therapy
IMS – Clear endorsement – long term therapy but individualise
EMAS – Best option in younger and symptomatic women
Alternatives more suitable in older women
NAMS – Definite evidence for effect – weigh risks:benefits against alternatives
![Page 32: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/32.jpg)
Indications
HRT should only be prescribed when it is clearly indicated
Vasomotor symptoms (there is no effective alternative)
Urogenital atrophy (Topical low-dose products are the treatment choice if only local symptoms present
Fracture risk reduction (HRT may be an initial option in woman at significantly increased fracture risk)
![Page 33: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/33.jpg)
Initiation of treatment
Sequential (SC) HRT:
Preferably progestogen-dominant
Bleed free continuous combined (CC) HRT can be recommended later
Switch from SC to CC HRT should meet the following criteria:
Patient is likely to be postmenopausal (age >50 years)
Patient should have had regular withdrawal bleeding and no irregular bleeding while taking SC HRT
Patient had no bleeding on SC HRT
Early initiation is important – it enables both relief of menopausal symptoms and protects against the consequences of oestrogen deficiency
Combined preparation should be used in women with intact uterus
![Page 34: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/34.jpg)
Initiation of treatment
All guidelines support early initiation
early relief of symptoms
possible early effects on systemic aspects
NAMS emphasises moderate/severe symptoms as indication
Early initiation is important – it enables both relief of menopausal symptoms and protects against the consequences of oestrogen deficiency
Combined preparation should be used in women with intact uterus
![Page 35: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/35.jpg)
Initiation of treatment
Sequential (SC) HRT:
Preferably progestogen-dominant
Bleed free continuous combined (CC) HRT can be recommended later
Switch from SC to CC HRT should meet the following criteria:
Patient is likely to be postmenopausal (age >50 years)
Patient should have had regular withdrawal bleeding and no irregular bleeding while taking SC HRT
Patient had no bleeding on SC HRT
Early initiation is important – it enables both relief of menopausal symptoms and protects against the consequences of oestrogen deficiency
Combined preparation should be used in women with intact uterus
![Page 36: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/36.jpg)
Initiation of treatment
Sequential (SC) HRT:
Preferably progestogen-dominant
Bleed free continuous combined (CC) HRT can be recommended later
Switch from SC to CC HRT should meet the following criteria:
Patient is likely to be postmenopausal (age >50 years)
Patient should have had regular withdrawal bleeding and no irregular bleeding while taking SC HRT
Patient had no bleeding on SC HRT
Early initiation is important – it enables both relief of menopausal symptoms and protects against the consequences of oestrogen deficiency
Combined preparation should be used in women with intact uterus
![Page 37: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/37.jpg)
Initiation of treatment
Sequential (SC) HRT:
Preferably progestogen-dominant
Bleed free continuous combined (CC) HRT can be recommended later
All guidelines accept that (CC) HRT will be main approach
All recognise that continuous progestogen effect
needs further research
Early initiation is important – it enables both relief of menopausal symptoms and protects against the consequences of oestrogen deficiency
Combined preparation should be used in women with intact uterus
![Page 38: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/38.jpg)
Initiation of treatment
Sequential (SC) HRT:
Preferably progestogen-dominant
Bleed free continuous combined (CC) HRT can be recommended later
Switch from SC to CC HRT should meet the following criteria:
Patient is likely to be postmenopausal (age >50 years)
Patient should have had regular withdrawal bleeding and no irregular bleeding while taking SC HRT
Patient had no bleeding on SC HRT
Early initiation is important – it enables both relief of menopausal symptoms and protects against the consequences of oestrogen deficiency
Combined preparation should be used in women with intact uterus
![Page 39: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/39.jpg)
Dose recommendation
Lowest effective dose should be used
Recommended starting doses include:
0.5 – 1mg 17β-oestradiol (oral)
0.3 – 0.45mg conjugated equine oestrogens (oral)
25 – 37.5µg transdermal (patch) oestradiol
0.5mg oestradiol gel
150µg intranasal oestradiol
![Page 40: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/40.jpg)
Dose recommendation
Lowest effective dose should be used
Recommended starting doses include:
0.5 – 1mg 17β-oestradiol (oral)
0.3 – 0.45mg conjugated equine oestrogens (oral)
25 – 37.5µg transdermal (patch) oestradiol
0.5mg oestradiol gel
150µg intranasal oestradiol
![Page 41: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/41.jpg)
Monitoring treatment
Pre-treatment assessment History Menopausal symptoms Menstrual history Personal and/or family history of Osteoporotic fracture VTE Breast cancer CVD
Physical examination incl. weight and blood pressure
Additional assessments may include/require Vaginal ultrasound and/or endometrial biopsy Mammography (frequency according to local guidelines) Bone mineral density based on local guidelines
Patients should be re-evaluated annually
![Page 42: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/42.jpg)
Monitoring treatment
Pre-treatment assessment History Menopausal symptoms Menstrual history Personal and/or family history of Osteoporotic fracture VTE Breast cancer CVD
Physical examination incl. weight and blood pressure
Additional assessments may include/require Vaginal ultrasound and/or endometrial biopsy Mammography (frequency according to local guidelines) Bone mineral density based on local guidelines
Patients should be re-evaluated annually
![Page 43: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/43.jpg)
Monitoring treatment
Pre-treatment assessment History Menopausal symptoms Menstrual history Personal and/or family history of Osteoporotic fracture VTE Breast cancer CVD
Physical examination incl. weight and blood pressure
Additional assessments may include/require Vaginal ultrasound and/or endometrial biopsy Mammography (frequency according to local guidelines) Bone mineral density based on local guidelines
Patients should be re-evaluated annually
![Page 44: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/44.jpg)
Duration of treatment
Based on the indication for treatment
Dose and type should be re-evaluated annually
Need for continuation can be determined by temporarily discontinuing therapy
Prevention or treatment of osteoporosis
Only long-term therapy is effective
Urogenital atrophy
Long-term therapy, usually topical, may be required
![Page 45: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/45.jpg)
Duration of treatment
Based on the indication for treatment
Dose and type should be re-evaluated annually
Need for continuation can be determined by temporarily discontinuing therapy
Prevention or treatment of osteoporosis
Only long-term therapy is effective
Urogenital atrophy
Long-term therapy, usually topical, may be required
![Page 46: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/46.jpg)
Duration of treatment
Based on the indication for treatment
Dose and type should be re-evaluated annually
Need for continuation can be determined by temporarily discontinuing therapy
Guidelines not entirely consistent
NAMS – extended treatment OK if…
benefit > risk but ? try to stop at intervals
no consensus on stopping – therefore individualise
no consensus on tapering
IMS – No new reason for mandatory limit
No reason to stop when symptom-free on treatment
![Page 47: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/47.jpg)
Duration of treatment
Based on the indication for treatment
Dose and type should be re-evaluated annually
Need for continuation can be determined by temporarily discontinuing therapy
Prevention or treatment of osteoporosis
Only long-term therapy is effective
Urogenital atrophy
Long-term therapy, usually topical, may be required
![Page 48: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/48.jpg)
Duration of treatment
Based on the indication for treatment
Dose and type should be re-evaluated annually
Need for continuation can be determined by temporarily discontinuing therapy
Prevention or treatment of osteoporosis
Only long-term therapy is effective
Agreed by all guidelines but differences on effect of this on approach
adopted
IMS – strongest view supporting use beyond early PM years
![Page 49: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/49.jpg)
Duration of treatment
Based on the indication for treatment
Dose and type should be re-evaluated annually
Need for continuation can be determined by temporarily discontinuing therapy
Prevention or treatment of osteoporosis
Only long-term therapy is effective
Urogenital atrophy
Long-term therapy, usually topical, may be required
![Page 50: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/50.jpg)
Duration of treatment
Based on the indication for treatment
Dose and type should be re-evaluated annually
Need for continuation can be determined by temporarily discontinuing therapy
Prevention or treatment of osteoporosis
Only long-term therapy is effective
Urogenital atrophy
Long-term therapy, usually topical, may be required
Good consensus across the guidelines in support of
local E-only therapy in extended use
![Page 51: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/51.jpg)
Conclusions
![Page 52: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/52.jpg)
Conclusions
The international groups demonstrate a good consensus on the use of HRT today
The central role of HRT in symptom relief is unchallenged
The detailed management approach is remarkably similar across the guidelines but all stress the need for individualisation
The longer-term benefits and risks remain controversial and influence longer-term management approaches even where effectiveness is clear – fracture prevention
All criticise a “too simplistic” interpretation of WHI
All agree that more evidence is needed concerning different…...
forms of estrogen and progestogen
routes of administration
levels of hormone dose
![Page 53: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/53.jpg)
Conclusions
The international groups demonstrate a good consensus on the use of HRT today
The central role of HRT in symptom relief is unchallenged
The detailed management approach is remarkably similar across the guidelines but all stress the need for individualisation
The longer-term benefits and risks remain controversial and influence longer-term management approaches even where effectiveness is clear – fracture prevention
All criticise a “too simplistic” interpretation of WHI
All agree that more evidence is needed concerning different…...
forms of estrogen and progestogen
routes of administration
levels of hormone dose
![Page 54: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/54.jpg)
Conclusions
The international groups demonstrate a good consensus on the use of HRT today
The central role of HRT in symptom relief is unchallenged
The detailed management approach is remarkably similar across the guidelines but all stress the need for individualisation
The longer-term benefits and risks remain controversial and influence longer-term management approaches even where effectiveness is clear – fracture prevention
All criticise a “too simplistic” interpretation of WHI
All agree that more evidence is needed concerning different…...
forms of estrogen and progestogen
routes of administration
levels of hormone dose
![Page 55: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/55.jpg)
Conclusions
The international groups demonstrate a good consensus on the use of HRT today
The central role of HRT in symptom relief is unchallenged
The detailed management approach is remarkably similar across the guidelines but all stress the need for individualisation
The longer-term benefits and risks remain controversial and influence longer-term management approaches even where effectiveness is clear – fracture prevention
All criticise a “too simplistic” interpretation of WHI
All agree that more evidence is needed concerning different…...
forms of estrogen and progestogen
routes of administration
levels of hormone dose
![Page 56: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/56.jpg)
Conclusions
The international groups demonstrate a good consensus on the use of HRT today
The central role of HRT in symptom relief is unchallenged
The detailed management approach is remarkably similar across the guidelines but all stress the need for individualisation
The longer-term benefits and risks remain controversial and influence longer-term management approaches even where effectiveness is clear – fracture prevention
All criticise a “too simplistic” interpretation of WHI
All agree that more evidence is needed concerning different…...
forms of estrogen and progestogen
routes of administration
levels of hormone dose
![Page 57: 2006 : TERAPIA ORMONALE SOSTITUTIVA DELLA MENOPAUSA CURRENT CONSENSUS GUIDELINES AND PRACTICE RECOMMENDATIONS Andrea R. Genazzani, MD, PhD, FRCOG President](https://reader034.vdocuments.us/reader034/viewer/2022051614/5519c782550346443e8b4706/html5/thumbnails/57.jpg)
Conclusions
The international groups demonstrate a good consensus on the use of HRT today
The central role of HRT in symptom relief is unchallenged
The detailed management approach is remarkably similar across the guidelines but all stress the need for individualisation
The longer-term benefits and risks remain controversial and influence longer-term management approaches even where effectiveness is clear – fracture prevention
All criticise a “too simplistic” interpretation of WHI
All agree that more evidence is needed concerning different…...
forms of estrogen and progestogen
routes of administration
levels of hormone dose